Song Jun-Seob, Hong Ki-Taek, Kim Na-Min, Hwangbo Byung-Hun, Yang Bong-Seok, Victoroff Brian N, Choi Nam-Hong
Department of Orthopedic Surgery, Gangnam JS Hospital, Seoul, Republic of Korea.
Department of Orthopedic Surgery, Nowon Eulji Medical Center, Eulji University, Seoul, Republic of Korea.
Orthop J Sports Med. 2023 Apr 24;11(4):23259671231158391. doi: 10.1177/23259671231158391. eCollection 2023 Apr.
There is a paucity of literature reporting clinical and magnetic resonance imaging (MRI) outcomes after allogeneic umbilical cord blood-derived mesenchymal stem cell (UCB-MSC) implantation for chondral defects of the knee.
To report clinical and MRI outcomes after UCB-MSC implantation for chondral lesions of the knee.
Case series; Level of evidence, 4.
Inclusion criteria were patients aged between 40 and 70 years with focal chondral lesions of grade 3 or 4 on the medial femoral condyle, defect sizes >4 cm, and intact ligaments. Exclusion criteria were patients who required realignment osteotomy or who had a meniscal deficiency, ligamentous instability, or a concomitant full-thickness chondral defect in the lateral or patellofemoral compartment. A mixture of human UCB-MSCs and sodium hyaluronate was implanted into the chondral defect through mini-arthrotomy. MRI at 1-year follow-up was performed to evaluate repaired cartilage hypertrophy. Repaired cartilage thickness was measured, and hypertrophy was classified as grade 1 (<125%), grade 2 (<150%), or grade 3 (<200%). Patient-reported outcomes (PROs; International Knee Documentation Committee, visual analog scale for pain, and Western Ontario and McMaster Universities Osteoarthritis Index) were evaluated preoperatively and at 1, 2, and 3 years postoperatively. Repaired cartilage hypertrophy was evaluated for a correlation with PRO scores.
Enrolled were 85 patients with a mean age of 56.8 ± 6.1 years and a mean chondral defect size of 6.7 ± 2.0 cm. At follow-up, a significant improvement in all PRO scores was seen compared with preoperatively ( < .001 for all). MRI at 1-year follow-up demonstrated that 28 patients had grade 1 repaired cartilage hypertrophy, 41 patients had grade 2, and 16 patients had grade 3. MRI performed in 11 patients at 2 years after surgery indicated no difference in repaired cartilage hypertrophy between the 1- and 2-year time points. The grade of repaired cartilage hypertrophy did not correlate with PRO scores.
Clinical outcomes improved significantly at short-term follow-up after UCB-MSC implantation. Although all patients showed repaired cartilage hypertrophy, it did not correlate with clinical outcomes.
关于同种异体脐带血间充质干细胞(UCB-MSC)植入治疗膝关节软骨损伤后的临床及磁共振成像(MRI)结果的文献报道较少。
报告UCB-MSC植入治疗膝关节软骨损伤后的临床及MRI结果。
病例系列;证据等级,4级。
纳入标准为年龄在40至70岁之间、股骨内侧髁局灶性软骨损伤为3级或4级、缺损尺寸>4 cm且韧带完整的患者。排除标准为需要进行截骨矫正术的患者,或存在半月板损伤、韧带不稳定或外侧或髌股关节间伴有全层软骨缺损的患者。通过小切口关节切开术将人UCB-MSCs和透明质酸钠的混合物植入软骨缺损处。在1年随访时进行MRI检查以评估修复软骨的肥大情况。测量修复软骨的厚度,并将肥大分为1级(<125%)、2级(<150%)或3级(<200%)。在术前以及术后1年、2年和3年评估患者报告的结果(PROs;国际膝关节文献委员会、疼痛视觉模拟量表以及西安大略和麦克马斯特大学骨关节炎指数)。评估修复软骨肥大与PRO评分之间的相关性。
纳入85例患者,平均年龄为56.8±6.1岁,平均软骨缺损尺寸为6.7±2.0 cm。随访时,与术前相比所有PRO评分均有显著改善(所有P<0.001)。1年随访时MRI显示,28例患者修复软骨肥大1级,41例患者为2级,16例患者为3级。术后2年对11例患者进行的MRI检查表明,1年和2年时间点的修复软骨肥大情况无差异。修复软骨肥大的分级与PRO评分无关。
UCB-MSC植入后短期随访时临床结果有显著改善。虽然所有患者均显示有修复软骨肥大,但它与临床结果无关。